Report

Update: Mutant KRAS to the fore

Recent initial results of Oncolytics’s NCI pancreatic cancer randomised Phase II trial showed a positive trend in median progression-free survival (PFS) between Reolysin in combination with carboplatin/paclitaxel and the sub-group of patients with mutant KRAS, but not in the overall patient population. However, results have not been viewed positively by investors. Reolysin is in six ongoing randomised Phase II trials, which are expected to deliver results in 2014-15. A positive result in any one of these trials could be a catalyst for the beleaguered share price.
Underlying
Oncolytics Biotech Inc.

Oncolytics Biotech is engaged in the discovery and development of pharmaceutical products, namely REOLYSIN® for the treatment of cancers that have not been successfully treated with conventional therapeutics. The product being developed by Co. may represent a novel treatment for Ras mediated cancers which can be used as an alternative to existing cytotoxic or cytostatic therapies, as an adjuvant therapy to conventional chemotherapy, radiation therapy, or surgical resections, or to treat certain cellular proliferative disorders for which no current therapy exists.

Provider
Edison Investment Research
Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

.

Other Reports on these Companies
Other Reports from Edison Investment Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch